FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007683982> ?p ?o ?g. }

• W2007683982 abstract "You have accessJournal of UrologyProstate Cancer: Advanced I1 Apr 2012680 PREDICTION OF FAVOURABLE OUTCOME AND RATIONAL INDICATION OF DOCETAXEL RECHALLENGE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER Matthias Heck, Mark Thalgott, Margitta Retz, Petra Wolf, Tobias Maurer, Jürgen Gschwend, and Hubert Kübler Matthias HeckMatthias Heck Munich, Germany More articles by this author , Mark ThalgottMark Thalgott Munich, Germany More articles by this author , Margitta RetzMargitta Retz Munich, Germany More articles by this author , Petra WolfPetra Wolf Munich, Germany More articles by this author , Tobias MaurerTobias Maurer Munich, Germany More articles by this author , Jürgen GschwendJürgen Gschwend Munich, Germany More articles by this author , and Hubert KüblerHubert Kübler Munich, Germany More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.762AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To identify predictors of favourable oncological outcome in metastatic castration-resistant prostate cancer (mCRPC) patients who are treated with docetaxel rechallenge following first-line chemotherapy with docetaxel. METHODS We retrospectively evaluated the oncological outcome of mCRPC patients who were treated with 3-weekly docetaxel (75mg/m2) at first-line chemotherapy and rechallenge plus prednisone/ prednisolone. The endpoints of oncological outcome were PSA-progression-free survival (PSA-PFS) and overall survival (OS) after initiation of docetaxel rechallenge. The effect of clinical variables on PSA-PFS and OS was statistically analysed by a log-rank test or Cox regression with hazard ratios. All analyses were performed using a 0.05 level of significance. RESULTS 47 patients were included on analysis. At a median follow-up of 25.8 months (range 9.8-89.8 months) after the first administration of docetaxel, 27 (57.4%) patients had died. Median PSA-PFS was 5.9 months (95% CI 3.5-6.8 months) and median OS was 21.4 months (95% CI 18.9-23.9 months) after initiation of docetaxel rechallenge. PSA-reduction ≥ 30% was the only pre-treatment variable that correlated significantly with prolonged PSA-PFS (p=0.03) and OS (p=0.002). Patients with PSA-reduction ≥ 30% at first-line chemotherapy showed a median OS of 21.8 months since initiation of docetaxel rechallenge in comparison to 4.5 months in patients with < 30% PSA-reduction. CONCLUSIONS Docetaxel rechallenge represents an active treatment option in selected docetaxel-pretreated patients with mCRPC. In this retrospective study, PSA-reduction ≥ 30% at first-line chemotherapy with docetaxel predicted superior PSA-PFS and OS in the rechallenge setting and might, therefore, present a rational indication for docetaxel rechallenge. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e277 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Matthias Heck Munich, Germany More articles by this author Mark Thalgott Munich, Germany More articles by this author Margitta Retz Munich, Germany More articles by this author Petra Wolf Munich, Germany More articles by this author Tobias Maurer Munich, Germany More articles by this author Jürgen Gschwend Munich, Germany More articles by this author Hubert Kübler Munich, Germany More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2007683982 created "2016-06-24" @default.
• W2007683982 creator A5003688542 @default.
• W2007683982 creator A5004874607 @default.
• W2007683982 creator A5024163450 @default.
• W2007683982 creator A5038906134 @default.
• W2007683982 creator A5039792880 @default.
• W2007683982 creator A5065439229 @default.
• W2007683982 creator A5067456208 @default.
• W2007683982 date "2012-04-01" @default.
• W2007683982 modified "2023-09-25" @default.
• W2007683982 title "680 PREDICTION OF FAVOURABLE OUTCOME AND RATIONAL INDICATION OF DOCETAXEL RECHALLENGE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER" @default.
• W2007683982 doi "https://doi.org/10.1016/j.juro.2012.02.762" @default.
• W2007683982 hasPublicationYear "2012" @default.
• W2007683982 type Work @default.
• W2007683982 sameAs 2007683982 @default.
• W2007683982 citedByCount "0" @default.
• W2007683982 crossrefType "journal-article" @default.
• W2007683982 hasAuthorship W2007683982A5003688542 @default.
• W2007683982 hasAuthorship W2007683982A5004874607 @default.
• W2007683982 hasAuthorship W2007683982A5024163450 @default.
• W2007683982 hasAuthorship W2007683982A5038906134 @default.
• W2007683982 hasAuthorship W2007683982A5039792880 @default.
• W2007683982 hasAuthorship W2007683982A5065439229 @default.
• W2007683982 hasAuthorship W2007683982A5067456208 @default.
• W2007683982 hasConcept C121608353 @default.
• W2007683982 hasConcept C126322002 @default.
• W2007683982 hasConcept C143998085 @default.
• W2007683982 hasConcept C207103383 @default.
• W2007683982 hasConcept C2775832370 @default.
• W2007683982 hasConcept C2777899217 @default.
• W2007683982 hasConcept C2780192828 @default.
• W2007683982 hasConcept C2781190966 @default.
• W2007683982 hasConcept C29456083 @default.
• W2007683982 hasConcept C44249647 @default.
• W2007683982 hasConcept C71924100 @default.
• W2007683982 hasConceptScore W2007683982C121608353 @default.
• W2007683982 hasConceptScore W2007683982C126322002 @default.
• W2007683982 hasConceptScore W2007683982C143998085 @default.
• W2007683982 hasConceptScore W2007683982C207103383 @default.
• W2007683982 hasConceptScore W2007683982C2775832370 @default.
• W2007683982 hasConceptScore W2007683982C2777899217 @default.
• W2007683982 hasConceptScore W2007683982C2780192828 @default.
• W2007683982 hasConceptScore W2007683982C2781190966 @default.
• W2007683982 hasConceptScore W2007683982C29456083 @default.
• W2007683982 hasConceptScore W2007683982C44249647 @default.
• W2007683982 hasConceptScore W2007683982C71924100 @default.
• W2007683982 hasIssue "4S" @default.
• W2007683982 hasLocation W20076839821 @default.
• W2007683982 hasOpenAccess W2007683982 @default.
• W2007683982 hasPrimaryLocation W20076839821 @default.
• W2007683982 hasRelatedWork W2568045406 @default.
• W2007683982 hasRelatedWork W2589688070 @default.
• W2007683982 hasRelatedWork W2770702948 @default.
• W2007683982 hasRelatedWork W2776594178 @default.
• W2007683982 hasRelatedWork W2912565296 @default.
• W2007683982 hasRelatedWork W2935114107 @default.
• W2007683982 hasRelatedWork W3023947295 @default.
• W2007683982 hasRelatedWork W4205706045 @default.
• W2007683982 hasRelatedWork W4226040508 @default.
• W2007683982 hasRelatedWork W4229076799 @default.
• W2007683982 hasVolume "187" @default.
• W2007683982 isParatext "false" @default.
• W2007683982 isRetracted "false" @default.
• W2007683982 magId "2007683982" @default.
• W2007683982 workType "article" @default.